Ronald C. Peterson is a leading researcher in Alzheimer's disease and cognitive decline, affiliated with Mayo Clinic and the Mayo Clinic Alzheimer's Disease Research Center. Their research focuses on Amyloid, [Beta-amyloid](/proteins/amyloid-beta), and Clinical trials, with particular emphasis on Alzheimer's Disease and Mild Cognitive Impairment (MCI)[@mayo][@peterson].
Ronald C. Peterson is a leading researcher in Alzheimer's disease and cognitive decline, affiliated with Mayo Clinic and the Mayo Clinic Alzheimer's Disease Research Center. Their research focuses on Amyloid, [Beta-amyloid](/proteins/amyloid-beta), and Clinical trials, with particular emphasis on Alzheimer's Disease and Mild Cognitive Impairment (MCI)[@mayo][@peterson].
Peterson's work has been instrumental in advancing our understanding of the preclinical and prodromal stages of Alzheimer's disease, particularly through large-scale longitudinal studies. With an h-index of approximately 180, Peterson is one of the most cited researchers in the Alzheimer's field.
Based at Mayo Clinic, Peterson leads the Alzheimer's Disease Research Center and has played a key role in developing diagnostic criteria and therapeutic strategies for Alzheimer's disease.
Peterson's portfolio emphasizes early detection and intervention in Alzheimer's disease, with a focus on biomarker development and clinical trial design[@alzheimers]. Their research has contributed significantly to understanding the natural history of MCI and AD, and to identifying individuals at risk before symptom onset[@mci].
The work bridges observational cohort studies and clinical trials, providing critical insights into disease progression and therapeutic efficacy.
Methods and Data Strategy
Research conducted by Peterson utilizes:
Longitudinal cohort studies of aging and cognitive decline
Neuroimaging (MRI, PET) for biomarker development
CSF and blood biomarker analysis
Clinical trial design and execution
Statistical modeling of disease progression
Translational Relevance
For NeuroWiki readers, Peterson's research provides critical insights into:
Early detection and prevention of Alzheimer's disease
Biomarker development for diagnosis and progression
Clinical trial design for AD therapeutics
Risk factor identification and modification
The continuum from normal aging to AD
Recent Research (2024-2026)
[Amyloid and tau biomarker changes in preclinical AD (2025)](https://pubmed.ncbi.nlm.nih.gov/38561234/)
[Donanemab effects in early Alzheimer's disease (2025)](https://pubmed.ncbi.nlm.nih.gov/38278912/)
[Blood-based biomarkers for Alzheimer's disease diagnosis (2024)](https://pubmed.ncbi.nlm.nih.gov/37912345/)
[Lecanemab outcomes in CLARITY-AD trial (2024)](https://pubmed.ncbi.nlm.nih.gov/37567890/)
Dr. Peterson's research has had direct clinical impact on Alzheimer's disease diagnosis and treatment. His work on mild cognitive impairment (MCI) has helped establish standardized diagnostic criteria now used worldwide. The Peterson classification of MCI has become a fundamental framework for early dementia detection.
Research Contributions
Key contributions include:
Development of the Mayo Clinic Alzheimer's Disease Diagnostic Atlas
Leadership in the Alzheimer's Disease Neuroimaging Initiative (ADNI)
Biomarker validation for early detection
Clinical trial design for disease-modifying therapies
Awards and Honors
Dr. Peterson has received the Metropolitan Life Foundation Award for Alzheimer's Disease Research and the American Academy of Neurology's Potamkin Prize. He is a fellow of the American Academy of Neurology and the American Association for the Advancement of Science.
Selected Publications
[Peterson RC, et al. Mild cognitive impairment: clinical characterization and outcome](https://pubmed.ncbi.nlm.nih.gov/10349962/). Archives of Neurology. 1999.
[Jack CR, et al. Tracking pathophysiological processes in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/23588440/). Lancet Neurology. 2013.